Escandon, Rafael D
BridgeBio (United States)
2 papers on CoChat
Most cited papers
- Verified
Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study
Teerlink, J. R., Clarke, C. P., Saikali, K. G., Lee, J. H., Chen, M. M., Escandon, R. D., Elliott, L., Bee, R., Habibzadeh, M. R., Goldman, J. H., et al. (2011) · The Lancet
Heart Failure Treatment and ManagementCardiomyopathy and Myosin Studies
Cited by 262
- Verified
Design of a Phase 1/2 Open-Label, Dose-Escalation Study of the Safety and Efficacy of Gene Therapy in Adults With Classic Congenital Adrenal Hyperplasia (CAH) Due to 21-hydroxylase Deficiency Through Administration of an Adeno-Associated Virus (AAV) Serotype 5-Based Recombinant Vector Encoding the Human CYP21A2 Gene
Merke, D. P., Auchus, R. J., Sarafoglou, K., Geffner, M. E., Kim, M. S., Escandon, R. D., Bharucha, K. N., Shaywitz, A. J., Eclov, R., Beard, C. W., et al. (2021) · Journal of the Endocrine Society
Virus-based gene therapy researchAdrenal Hormones and Disorders
Cited by 7
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free